New Delhi, Jan 18 (PTI) Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator to market its generic Febuxostat tablets, indicated for the chronic management of hyperuricemia in adult patients with gout.

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Febuxostat tablets of strengths 40 mg and 80 mg, a generic equivalent of Uloric tablets, 40 mg and 80 mg, of Takeda Pharmaceuticals USA, Inc, Lupin said in a regulatory filing.

Also Read | Netizens Celebrate Ram Mandir Pran Pratishtha Ceremony Preparations in Ayodhya! Check Out Posts, Pics & Videos Online Capturing the Excitement Leading Up to the Event.

The product will be manufactured at the company's Pithampur facility in India, it added.

The company said Febuxostat tablets of strengths 40 mg and 80 mg are indicated for the chronic management of hyperuricemia (elevated serum uric acid level) in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol; who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

Also Read | Ayodhya Dham Junction Railway Station Facts: Know All About New Ayodhya Railway Station That Has Airport-Like Amenities and More.

Febuxostat tablets had estimated annual sales of USD 27 million in the US, Lupin said citing IQVIA MAT November 2023 data.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)